The full regulatory document can be accessed through the London Stock Exchange or financial news platforms like ADVFN . Interim results for the 6 months ended 30 June 25
: £13.0 million (+52.9%), driven by AMR and EMEAI growth. The full regulatory document can be accessed through
: £12.9 million (+27.4%), supported by synthetic biology. The full regulatory document can be accessed through
: Established a strategic collaboration with Cepheid (a Danaher subsidiary) to develop automated infectious disease sequencing solutions. Leadership Update The full regulatory document can be accessed through
: Introduced next-generation automated flow cell lines and strengthened quality assurance to ISO 13485 standards.
: Completed a programme resulting in an approximately 5% reduction in workforce to reallocate capital to growth areas.